Shanmuga Hospital Ltd (544365)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Shanmuga Hospital's revenue was ₹11.9 Cr (+3.4% year on year, -48.0% on the previous quarter), and net profit ₹1.0 Cr (+3.8% year on year); the operating margin was 17.7%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹11.9 | +3.4% | -48.0% |
| Operating profit | ₹2.1 | +0.1% | -43.6% |
| Net profit | ₹1.0 | +3.8% | -55.2% |
| EPS (₹) | 0.72 | +2.9% | -55.6% |
| Operating margin | 17.7% | — | — |
📢 Recent Corporate Announcements
Shanmuga Hospital Limited announced that shareholders approved an increase in the company's authorised share capital from ₹14.00 crore to ₹25.00 crore at its 6th Annual General Meeting held on September 18, 2026. The capital is now divided into 2.50 crore equity shares of ₹10 each, up from 1.40 crore shares. This amendment to Clause V of the Memorandum of Association is subject to final approval from the Registrar of Companies (ROC). An increase in authorised capital creates headroom for future equity fundraising, bonus issues, or corporate actions.
- Authorised share capital increased from ₹14,00,00,000 to ₹25,00,00,000
- Total authorized equity shares expanded from 1,40,00,000 to 2,50,00,000 shares of ₹10 each
- Approved by shareholders at the 6th AGM held on September 18, 2026
- Amendment to Clause V of the Memorandum of Association is subject to ROC approval
Shanmuga Hospital Limited announced shareholder approval from its 6th Annual General Meeting held on September 18, 2026, to amend its Memorandum of Association (MOA) and Articles of Association (AOA). The MOA amendment adds two new business activities under Clause III(a): providing support and consultancy services to medical institutions, and developing/licensing healthcare software and digital applications. The AOA amendments align clauses regarding share capital, variation of rights, and further issue of share capital. These changes broaden corporate scope but do not immediately affect current revenue (TTM revenue of Rs 83 Cr) and are subject to ROC approval.
- Shareholders approved special resolutions at the 6th AGM on September 18, 2026
- Clause III(a) of MOA amended to add support and consultancy services to medical/nursing institutions
- Clause III(a) also expanded to cover software development, licensing, and digital healthcare solutions
- Articles of Association altered regarding share capital structure and further issues under Item No 6
- Implementation of MOA amendments remains subject to approval by the Registrar of Companies (ROC)
Shanmuga Hospital Limited submitted its 6th Annual Report for FY 2025-26 along with the Notice of Annual General Meeting scheduled for September 18, 2026. For FY26, the company reported revenue from operations of ₹4,743.61 Lakhs (₹47.44 Cr) and profit after tax of ₹421.06 Lakhs (₹4.21 Cr), with basic EPS at ₹3.09. The report highlighted the operationalization of its Robotic Surgical System funded via IPO proceeds, alongside ₹993.13 Lakhs encashed from term deposits to fund capital expenditures during the year.
- FY26 Revenue from operations stood at ₹4,743.61 Lakhs with PAT of ₹421.06 Lakhs and EPS of ₹3.09
- 6th Annual General Meeting (AGM) scheduled for Friday, September 18, 2026, at 02:30 PM IST via VC/OAVM
- Net worth stood at ₹4,250.19 Lakhs as of March 31, 2026, with D/E ratio improving to 0.16x from 0.19x
- Term deposits worth ₹993.13 Lakhs were encashed during FY26 to fund hospital capital expenditures including robotic surgical systems
Shanmuga Hospital Limited has issued notice for its 6th Annual General Meeting scheduled for September 18, 2026. Key special resolutions include increasing the authorised share capital from ₹14.00 crore to ₹25.00 crore (2.50 crore equity shares of ₹10 face value) and adopting the ESOP Plan 2026 covering up to 3,50,000 options (2.57% of paid-up equity). The company is also amending its Memorandum of Association to add healthcare IT/software development and institutional medical support services to its main business objects.
- Authorised share capital proposed to increase from ₹14.00 crore to ₹25.00 crore (2.50 crore shares of ₹10 each)
- Proposed ESOP Plan 2026 with up to 3,50,000 options, representing 2.57% of paid-up equity capital
- AGM scheduled for Friday, September 18, 2026 at 02:30 PM via Video Conference
- Main object clause amended to include healthcare software solutions and allied support services to medical colleges
Shanmuga Hospital's board has approved a significant 78.5% increase in authorized share capital from ₹14 crore to ₹25 crore, signaling potential future fundraising or corporate actions. The company is also introducing the 'SHL ESOP-2026' scheme, covering 3,50,000 shares (2.58% of equity) to incentivize employees. Strategically, the company is diversifying its business by amending its Memorandum of Association to include medical consultancy and software development. Additionally, a Power Purchase Agreement was signed at a tariff of ₹6.10 per unit to optimize operational costs.
- Authorized share capital increased from ₹14,00,00,000 to ₹25,00,00,000 to support future growth.
- New ESOP-2026 plan approved for 3,50,000 equity shares, representing 2.58% of total paid-up capital.
- Power Purchase Agreement (PPA) signed with LNGS Private Limited at a tariff of ₹6.10 per unit.
- Proposed diversification into medical education consultancy and digital/software application development.
- Annual General Meeting (AGM) scheduled for September 18, 2026, with a record date of September 11, 2026.
Shanmuga Hospital's board has approved a 78.6% increase in authorized share capital from ₹14 Cr to ₹25 Cr, signaling potential future equity issuances. The company introduced the 'SHL ESOP-2026' plan covering 3,50,000 shares, which represents a 2.58% dilution of the current paid-up capital. Strategically, the company is diversifying its business objects to include medical consultancy and digital software solutions. It also entered a Power Purchase Agreement (PPA) with LNGS Private Limited at a tariff of ₹6.10 per unit to optimize energy costs.
- Authorized share capital increased by ₹11 Cr to a new limit of ₹25 Cr
- New ESOP 2026 plan covers 3,50,000 equity shares, representing 2.58% of paid-up capital
- Power Purchase Agreement signed with LNGS Private Limited at a tariff of ₹6.10 per unit
- Company to invest 1% in the paid-up capital of power supplier LNGS Private Limited
- Main Object Clause amended to include medical consultancy and software development services
Shanmuga Hospital's board has approved a series of structural changes, including a new ESOP plan for 3,50,000 shares (2.58% of capital) and a Power Purchase Agreement (PPA) with LNGS Private Limited at ₹6.10 per unit. The company is seeking to increase its authorized share capital by 78.5%, from ₹14 crore to ₹25 crore, signaling potential future fundraising or corporate actions. Additionally, the board proposed diversifying into medical consultancy and digital healthcare software development. While Q1 FY27 results were approved, the specific financial figures were not detailed in this summary extract.
- Approved ESOP 2026 plan for 3,50,000 equity shares, representing 2.58% of total paid-up capital.
- Proposed increase in Authorized Share Capital from ₹14 crore to ₹25 crore, subject to AGM approval.
- Entered a PPA with LNGS Private Limited at a tariff of ₹6.10 per unit; includes a 1% equity investment in the power provider.
- Proposed alteration of Main Object Clause to include medical consultancy and software/digital healthcare solutions.
- 6th Annual General Meeting (AGM) scheduled for September 18, 2026, with a record date of September 11, 2026.
Shanmuga Hospital's board has approved a significant 78.5% increase in authorized share capital from ₹14 Cr to ₹25 Cr, signaling potential future equity fundraising or corporate actions. The company is diversifying its business scope to include medical education consultancy and software development services. Additionally, a new ESOP scheme for 3,50,000 shares (2.58% of capital) and a Power Purchase Agreement at ₹6.10 per unit were cleared. These moves indicate a strategic shift toward broader healthcare services and operational cost management.
- Authorized share capital increased from ₹14 Cr to ₹25 Cr to support future growth plans.
- Formulated 'SHL ESOP-2026' for 3,50,000 equity shares, representing 2.58% of total paid-up capital.
- Entered a Power Purchase Agreement with LNGS Private Limited at a tariff of ₹6.10 per unit.
- Proposed diversification into medical education consultancy and digital/software solutions for healthcare.
- Fixed the 6th Annual General Meeting (AGM) for September 18, 2026, with a record date of September 11, 2026.
Shanmuga Hospital Ltd has scheduled a board meeting for August 11, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. Beyond earnings, the board will consider the adoption of the 'Shanmuga Hospital Limited Employee Stock Option Plan 2026' to incentivize employees. The meeting will also finalize the details for the company's 6th Annual General Meeting (AGM). This follows a fiscal year (FY26) where the company reported a revenue of ‹ 47.44 Cr and a net profit of ‹ 4.21 Cr.
- Board meeting scheduled for August 11, 2026, to approve Q1 FY27 results.
- Proposal for 'Employee Stock Option Plan 2026' to be considered for staff retention.
- Trading window for securities has been closed since July 01, 2026.
- Company to finalize the date and mode for its 6th Annual General Meeting.
- FY26 annual revenue stood at ‹ 47.44 Cr with an operating margin of 17.45%.
Shanmuga Hospital has launched the pilot testing phase for its integrated digital healthcare application, "Shanmuga 360," on July 13, 2026. The app is now available on the Google Play Store and Apple App Store for performance validation and user feedback collection. This phase involves a controlled, phased rollout of features and does not constitute a formal commercial launch. The company intends to monitor operational stability and security before a full-scale release.
- Initiated pilot public testing of the "Shanmuga 360" mobile application on July 13, 2026
- Application made available on 2 major platforms: Google Play Store and Apple App Store
- Testing phase involves controlled enablement of features to ensure security and service efficiency
- Official commercial launch is pending successful completion of the current validation process
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
